SCHEMBL2624070

SCHEMBL2624070

COc1ccc(COCSC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.53
AGXT P21549 2/20 0.53
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
APP P05067 7/20 0.47
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAOB P27338 1/20 0.46
CALM1 P0DP23 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
LTA4H P09960 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HTT P42858 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34413 0.83 IDO1 (0.67) IDO1AGXTCA1CA2APP
Potassium SCHEMBL1477050 0.81 IDO1 (0.64) IDO1AGXTCA1CA2APP
SCHEMBL1475481 0.81 IDO1 (0.64) IDO1AGXTCA1CA2APP
SCHEMBL11021975 0.79 AGXT (0.50) IDO1AGXTCA1CA2MAOB
SCHEMBL8499580 0.79 IDO1 (0.61) IDO1AGXTCA1CA2APP
SCHEMBL10813123 0.78 LTA4H (0.36) IDO1AGXTCA1CA2CA12
SCHEMBL2618879 0.77 IDO1 (0.59) IDO1AGXTCA1CA2APP
SCHEMBL11132718 0.77 IDO1 (0.59) IDO1AGXTCA1CA2APP
SCHEMBL52777 0.77 IDO1 (0.59) IDO1AGXTCA1CA2APP
SCHEMBL11132720 0.77 LTA4H (0.65) IDO1AGXTCA1CA2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119301119-A Novel indenone derivatives and use thereof 淀粉样蛋白解决方案株式会社 2025-01-10 CN disclosed
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 US disclosed
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 US disclosed
WO-2012054874-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, EIF4A2 IDO1 859/4885AGXT 185/4885CA1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.